
|Articles|September 1, 2007
- Psychiatric Times Vol 24 No 10
- Volume 24
- Issue 10
New Patient
Author(s)Richard M. Berlin, MD
Poetry of the Times
Advertisement
If you have read my poems you know
I am a man who rides trains facing backwards,
which is how I read books of poetry,
last poem first, the way I will read
the lesions on your arms
like lines from a tattered timetable
as we follow your tracks
back to that sunrise at the station
when your creases were sharp
and your wallet bulged with big bills,
her perfume clinging to your collar,
your dark eyes dancing down a line
toward a future you never imagined
would include this morning with me.
Articles in this issue
about 19 years ago
Clinical Depression: Complexities of Diagnosis and Managementabout 19 years ago
The Substance Abuse Handbookabout 19 years ago
Placebo Effects on Pharmacotherapy Outcomes in Major Depressionabout 19 years ago
Never-Ending Winter: Chronic Depressionabout 19 years ago
SSRIs and Pregnancy: Putting the Risks Into Perspectiveabout 19 years ago
Can We Predict Response to Antidepressants?about 19 years ago
Not Obsolete: Continuing Roles for TCAs and MAOIsAdvertisement
Related to this article

Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.

Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.

A critical care physician explains why quiet, hypoactive ICU delirium is often missed and why its effects follow patients long after discharge.

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder
2
Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive Disorder
3
Rethinking Restrictive, Repetitive Behaviors in Autism
4
Morning Rounds: News From November 9-16
5



